Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HiCM 188

Next Previous
X
Search
Drug Profile

HiCM 188

Alternative Names: Allogeneic induced pluripotent cell derived cardiomyocytes (iPSC-CMs) therapy - Help Therapeutics; HiCM-188; hiPSC-CM therapy - Help Therapeutics; induced pluripotent stem cell-derived cardiomyocyte therapy - Help Therapeutics

Latest Information Update: 04 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Help Therapeutics
  • Class Cardiovascular therapies; Cell therapies; Induced pluripotent stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Heart failure

Most Recent Events

  • 05 Sep 2023 Phase-I/II clinical trials in Heart failure (In adults, In the elderly) in China (Intracardiac) (NCT06340048)
  • 30 Jan 2023 NMPA approves IND for HiCM 188 for Heart failure
  • 30 Sep 2022 Help Therapeutics plans an early phase I trial for Chronic heart failure in China by September 2022 (Injection)(NCT05566600)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top